No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

• Published in: Frontiers in pharmacology Vol. 11; p. 1071
• Main Authors: Huang, Yin-Qiu, Tang, Sheng-Quan, Xu, Xiao-Lei, Zeng, Yan-Ming, He, Xiao-Qing, Li, Yao, Harypursat, Vijay, Lu, Yan-Qiu, Wan, Yan, Zhang, Lu, Sun, Qiang-Zhong, Sun, Nan-Nan, Wang, Gui-Xue, Yang, Zhong-Ping, Chen, Yao-Kai
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.07.2020
• Subjects: effectiveness and safety; interferon-alpha; lopinavir/ritonavir; mild to moderate COVID-19; Pharmacology; ribavirin; lopinavir/ritonavir; interferon-alpha; effectiveness and safety; ribavirin; mild to moderate COVID-19

Currently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiviral treat...